Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 173 matching trials from the live ClinicalTrials.gov search.
Filters: Coral Gables, Florida Clear all
Active, not recruiting Not applicable Interventional

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Completed No phase listed Observational

A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

NCT04733989
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 23, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

NCT02734537
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
Drug · Radiation · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
679
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 450 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

NCT05241860
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration, Quality-of-Life Assessment
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
326
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 234 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

NCT03983824
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Etoposide Phosphate, Mitoxantrone Hydrochloride, Multigated Acquisition Scan, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

NCT04559139
View directory record Official record
Conditions
Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
Interventions
Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy, Partial Hepatectomy
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
367
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant, Recurrent Astrocytoma, IDH-Mutant, Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions
Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Triapine
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Duarte, California • Irvine, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Early Phase 1 Interventional

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

NCT04494113
View directory record Official record
Conditions
Endometrial Serous Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Resection, Triapine
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 3 Interventional

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

NCT04155034
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Interventions
Magnetic Resonance Imaging, Prophylactic Cranial Irradiation
Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
428
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

NCT03816358
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

NCT04175912
View directory record Official record
Conditions
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Cholangiocarcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Carboplatin, Paclitaxel, Pevonedistat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
419
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Suspended Phase 3 Interventional

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

NCT06568172
View directory record Official record
Conditions
Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Surgical Procedure
Procedure · Biological · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
196
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

NCT03377556
View directory record Official record
Conditions
ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1151
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 2 Interventional

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

NCT04166318
View directory record Official record
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
659
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma

NCT02775812
View directory record Official record
Conditions
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
69
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

NCT04929041
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
169
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional Results available

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

NCT02927249
View directory record Official record
Conditions
Node Positive HER2 Negative Breast Cancer
Interventions
Placebo, Aspirin
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1426
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

NCT01989585
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Navitoclax, Pharmacological Study, Trametinib
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
49
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Recruiting Phase 1 Interventional

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

NCT07332507
View directory record Official record
Conditions
Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Teclistamab
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
20
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

NCT05451004
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Lymphatic Mapping with SPECT-CT, Ipsilateral and Contralateral Neck
Other · Radiation
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
28
States / cities
Corona, California • Duarte, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 2 Interventional

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

NCT05554367
View directory record Official record
Conditions
Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Palbociclib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
264
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 206 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
51
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Suspended Phase 3 Interventional

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

NCT06671912
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
728
States / cities
Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 5:26 PM EDT